MLchartDataset catalogue

anti-PD-L1/anti-VEGF bispecific antibody fusion protein B1962

Term · Oncology and biomedicine · MLC-T-ONC-011022

A bispecific antibody fusion protein composed of an immunoglobulin G1 (IgG1) monoclonal antibody targeting the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and fused to anti-vascular endothelial growth factor (VEGF) protein, with potential immune checkpoint inhibitory, anti-angiogenic and antineoplastic activities. Upon administration, anti-PD-L1/anti-VEGF bispecific antibody fusion protein B1962 targets and simultaneously binds to both PD-L1 and VEGF expressed on tumor cells. This prevents the binding of PD-L1 to its receptor, programmed cell death protein 1 (PD-1, CD279), inhibits the PD-1-mediated signaling, and inhibits the PD-1-mediated downregulation of T-cell activation and proliferation. This restores and enhances a cytotoxic T-lymphocyte (CTL)-mediated immune response against VEGF-expressing tumor cells. The binding of B1962 to VEGF prevents the binding of VEGF to its receptor VEGFR, abrogates VEGF/VEGFR-mediated signaling and may lead to the inhibition of vascular endothelial cell proliferation. The inhibition of tumor angiogenesis may further decrease tumor cell proliferation and prevent metastasis. PD-L1 is overexpressed in many human cancer cell types and plays an important role in the downregulation of the immune system and tumor evasion from host immunity. VEGF is overexpressed in a variety of cancers and is associated with increased invasiveness and decreased survival.

Table 1. Record
IdentifierMLC-T-ONC-011022
FieldOncology and biomedicine
Synonymsanti-PD-L1/VEGF bispecific antibody fusion protein B1962; PD-L1/VEGF bispecific antibody fusion protein B1962; PD-L1 x VEGF bispecific antibody fusion protein B1962
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-011022",
  "term": "anti-PD-L1/anti-VEGF bispecific antibody fusion protein B1962",
  "field": "Oncology and biomedicine",
  "definition": "A bispecific antibody fusion protein composed of an immunoglobulin G1 (IgG1) monoclonal antibody targeting the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and fused to anti-vascular endothelial growth factor (VEGF) protein, with potential immune checkpoint inhibitory, anti-angiogenic and antineoplastic activities. Upon administration, anti-PD-L1/anti-VEGF bispecific antibody fusion protein B1962 targets and simultaneously binds to both PD-L1 and VEGF expressed on tumor cells. This prevents the binding of PD-L1 to its receptor, programmed cell death protein 1 (PD-1, CD279), inhibits the PD-1-mediated signaling, and inhibits the PD-1-mediated downregulation of T-cell activation and proliferation. This restores and enhances a cytotoxic T-lymphocyte (CTL)-mediated immune response against VEGF-expressing tumor cells. The binding of B1962 to VEGF prevents the binding of VEGF to its receptor VEGFR, abrogates VEGF/VEGFR-mediated signaling and may lead to the inhibition of vascular endothelial cell proliferation. The inhibition of tumor angiogenesis may further decrease tumor cell proliferation and prevent metastasis. PD-L1 is overexpressed in many human cancer cell types and plays an important role in the downregulation of the immune system and tumor evasion from host immunity. VEGF is overexpressed in a variety of cancers and is associated with increased invasiveness and decreased survival.",
  "synonyms": [
    "anti-PD-L1/VEGF bispecific antibody fusion protein B1962",
    "PD-L1/VEGF bispecific antibody fusion protein B1962",
    "PD-L1 x VEGF bispecific antibody fusion protein B1962"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-pd-l1-anti-vegf-bispecific-antibody-fusion-protein-b1962/"
}

Record 2,152 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.